Potential Risk of Encephalopathy using Ceftriaxone-containing products (Health Canada)
Potential Risk of Encephalopathy using Ceftriaxone-containing products (Health Canada)
On 03 February 2021, Health Canada issued a Summary Safety Review of potential risk of encephalopathy using Ceftriaxone-containing products.
This review was triggered by a study published in the Journal of the Neurological Sciences.
Ceftriaxone is a prescription antibiotic drug authorized for sale in Canada to treat a wide range of bacterial infections in many different parts of the body or to prevent infections during surgery.
Health Canada’s review of the available information concluded that there may be a link between the use of ceftriaxone-containing products and the risk of encephalopathy.
Health Canada will work with the manufacturers of ceftriaxone-containing products to update the Canadian product safety information to include the risk of encephalopathy.
Health Canada encourages consumers and healthcare professionals to report any side effects related to the use of ceftriaxone-containing products and other health products to the Canada Vigilance Program.
Health Canada will continue to monitor safety information involving ceftriaxone-containing products, as it does for all health products on the Canadian market, to identify and assess potential harms. Health Canada will take appropriate and timely action should new health risks be identified.
Potential Risk of Encephalopathy using Ceftriaxone-containing products (Health Canada)
To know more@ Health Canada, Click here.
Drug Safety Communication FDA Risk of Serious Heart Related Problems And Cancer Tofacitinib
Safety Signal Risk of Acute Adrenal Insufficiency Hydrocortisone
FDA alerts: Potential risks associated with the compounding of remdesivir drug products
